SXTP Key Statistics, Chart & Performance
The current stock price of SXTP is 0.5125 USD. In the past month the price decreased by -46.73%. In the past year, price decreased by -90.24%.
SXTP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 49.35 | 1.03T | ||
| JNJ | JOHNSON & JOHNSON | 19.82 | 495.71B | ||
| MRK | MERCK & CO. INC. | 12.6 | 275.48B | ||
| PFE | PFIZER INC | 7.9 | 143.79B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.52 | 113.80B | ||
| ZTS | ZOETIS INC | 20.01 | 55.90B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.8 | 23.24B | ||
| VTRS | VIATRIS INC | 5.41 | 14.51B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.21 | 11.55B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.45B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.72B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.05B |
Related stock screener links
About SXTP
Company Profile
60 Degrees Pharmaceuticals, Inc. develops medicines for the treatment and prevention of infectious diseases. The company is headquartered in Washington, Washington Dc and currently employs 3 full-time employees. The company went IPO on 2023-07-12. The firm specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. The company is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. The company is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
Company Info
60 DEGREES PHARMA INC
1025 Connecticut Avenue Nw, Suite 1000
WASHINGTON WASHINGTON DC US
Employees: 3
Phone: 12023275422
60 DEGREES PHARMA INC / SXTP FAQ
What does SXTP do?
60 Degrees Pharmaceuticals, Inc. develops medicines for the treatment and prevention of infectious diseases. The company is headquartered in Washington, Washington Dc and currently employs 3 full-time employees. The company went IPO on 2023-07-12. The firm specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. The company is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. The company is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
What is the stock price of 60 DEGREES PHARMA INC today?
The current stock price of SXTP is 0.5125 USD. The price increased by 3.98% in the last trading session.
Does SXTP stock pay dividends?
SXTP does not pay a dividend.
What is the ChartMill technical and fundamental rating of SXTP stock?
SXTP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the expected growth for SXTP stock?
The Revenue of 60 DEGREES PHARMA INC (SXTP) is expected to grow by 164.27% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the ownership structure of 60 DEGREES PHARMA INC (SXTP)?
You can find the ownership structure of 60 DEGREES PHARMA INC (SXTP) on the Ownership tab.
SXTP Technical Analysis
SXTP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SXTP. SXTP may be in some trouble as it scores bad on both profitability and health.
SXTP Financial Highlights
Over the last trailing twelve months SXTP reported a non-GAAP Earnings per Share(EPS) of -17.67. The EPS increased by 61.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -126.7% | ||
| ROE | -191.31% | ||
| Debt/Equity | 0.03 |
SXTP Forecast & Estimates
8 analysts have analysed SXTP and the average price target is 4.49 USD. This implies a price increase of 775.71% is expected in the next year compared to the current price of 0.5125.
For the next year, analysts expect an EPS growth of 91.22% and a revenue growth 164.27% for SXTP